.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 3,892,744

« Back to Dashboard

Details for Patent: 3,892,744

Title: Process for preparing 4-[3-(substituted amino)-2-hydroxypropoxy]-1,2,5-thiadiazoles
Abstract:Preparation of S-3-X-4-(3-substituted amino-2-hydroxypropoxyl)-1,2,5-thiadiazole .beta.-adrenergic blocking agents using as starting material an optically active oxazolidine in the sinister configuration which is reacted with a 3-X-4-RO-1,2,5-thiadiazole.
Inventor(s): Weinstock; Leonard M. (Belle Mead, NJ), Tull; Roger J. (Metuchen, NJ), Mulvey; Dennis M. (Milford, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Filing Date:Dec 18, 1973
Application Number:05/425,912
Claims:1. A process for the preparation of an optically active thiadiazole in the sinister configuration having the structure S-III, ##SPC8##

comprising the reaction of a compound of structure I with a compound of structure S-II, ##SPC9##

followed by acid hydrolysis wherein the variable radical X is selected from chloro, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, phenyl, benzyl, morpholino, piperidino, hydroxypiperidino, and N-C.sub.1-3 alkyl-1-piperazinyl, Y is a straight or branched chain C.sub.1-5 alkyl; Z is hydrogen or an aliphatic, alicyclic, aromatic or heterocyclic residue of the aldehyde ZCHO used to form the oxazolidine nucleus; and R.sup.3 is alkylsulfonyl, arylsulfonyl or aralkylsulfonyl.

2. A process as in claim 1 wherein the reaction is carried out at a temperature between about 0.degree. to reflux.

3. A process as in claim 2 wherein reactant I is the sodium salt of 3-morpholino-4-hydroxy-1,2,5-thiadiazole and reactant S-II is S-3-tert-butyl-5-(p-toluenesulfonyloxymethyl)-oxazolidine to provide S-(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazol e.

4. A process as in claim 2 wherein reactant I is the sodium salt of 3-morpholino-4-hydroxy-1,2,5-thiadiazole and reactant S-II is S-3-tert-butyl-5-(p-nitrophenylsulfonyloxymethyl)-oxazolidine to provide S-(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazol e.

5. A process as in claim 2 wherein reactant I is the sodium salt of 3-morpholino-4-hydroxy-1,2,5-thiadiazole and reactant S-II is S-3-tert-butyl-5-(p-bromobenzenesulfonyloxymethyl)-oxazolidine to provide S-(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazol e.

6. The process as in claim 2 wherein reactant I is the sodium salt of 3-morpholino-4-hydroxy-1,2,5-thiadiazole and reactant S-II is S-3-tert-butyl-5-(benzenesulfonyloxymethyl) oxazolidine to provide S-(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazol e.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc